LONGEVERON, LLC

MIAMI, FL · Founded 2014 · Biotech · Public

Allogeneic mesenchymal stem cell (LMSC) therapeutic for aging frailty

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · longeveron.com

Sector: Biotech
Headquarters: MIAMI, FL
Founded: 2014
Latest Form D: $15.9M, Mar 2026
Total capital: $42M

Federal grants: $5.3M; 6 awards · 2017–2020; Rank in peer group#147 of 514
Private capital raised: $36.8M; 9 Form D · last Mar 2026; 7 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 9 pending

Capital timeline

Latest events

Mar 2026Private capital raisedForm D · SEC · 9th filing$15.9M
Jul 2024Offering registeredForm D · SEC · 8th filing$9.5M
Jun 2024Offering registeredForm D · SEC · 7th filing$9.4M
Apr 2024Offering registeredForm D · SEC · 6th filing$12.4M
Jan 2024Offering registeredForm D · SEC · 5th filing$2.6M
Oct 2023Offering registeredForm D · SEC · 4th filing$8.4M
Dec 2021Private capital raisedForm D · SEC · 3rd filing$20.5M
Feb 2020Private capital raisedForm D · SEC · 2nd filing$100K
Nov 2017Private capital raisedForm D · SEC · 1st filing$300K

Show 6 earlier federal awards

Jun 2020Federal grantHealth and Human S · Phase II · A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$436K
Mar 2020Federal grantHealth and Human S · Phase II · A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$2M
Jun 2019Federal grantHealth and Human S · Phase II · A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$465K
Apr 2019Federal grantHealth and Human S · Phase II · A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$2M
Sep 2018Federal grantHealth and Human S · Phase II · A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty$283K
Sep 2017Federal grantHealth and Human S · Phase II · A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

1month

from LONGEVERON, LLC’s first federal award to its first private round.

First federal award · Sep 2017: Health and Human S · $150K
First Form D · Nov 2017: $300K · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#147 · top 29%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Joshua M. HareResearcherExecutive Officer, DirectorLinked by $1.1M in grants as PI
Cathy E. RossDirectorNamed in SEC Form D filings
Devin A. BlassExecutive OfficerNamed in SEC Form D filings
Donald M. SofferDirectorNamed in SEC Form D filings
Douglas E. LosordoDirectorNamed in SEC Form D filings
Erin BorgerDirectorNamed in SEC Form D filings

Show all 23 people

Geoff M. GreenExecutive OfficerNamed in SEC Form D filings
George Joseph Paletta, Jr.DirectorNamed in SEC Form D filings
James E. ClavijoExecutive OfficerNamed in SEC Form D filings
Jeffrey E. PfefferDirectorNamed in SEC Form D filings
Khoso E. BaluchDirectorNamed in SEC Form D filings
Lisa A. LocklearExecutive OfficerNamed in SEC Form D filings
Nataliya A. AgafonovaExecutive OfficerNamed in SEC Form D filings
Neha J. MotwaniDirectorNamed in SEC Form D filings
Neil E. HareDirectorNamed in SEC Form D filings
Paul A. LehrExecutive OfficerNamed in SEC Form D filings
Richard E. KenderDirectorNamed in SEC Form D filings
Rock E. SofferDirectorNamed in SEC Form D filings
Roger Joseph HajjarDirectorNamed in SEC Form D filings
Stephen H. WillardExecutive OfficerNamed in SEC Form D filings
Suzanne M. PageExecutive OfficerNamed in SEC Form D filings
Ursula E. UngaroDirectorNamed in SEC Form D filings
Wa'El HashadExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 9

PendingTreatment of Alzheimer's Disease With Allogeneic Mesenchymal Stem CellsUSPTOApplication 63134535
PendingTreatment of Alzheimer's Disease With Allogeneic Mesenchymal Stem CellsUSPTOApplication 63075686
PendingPotency AssayUSPTOApplication 63012884

Show all 9 patent records

Treatment of Alzheimer's Disease With Allogeneic Mesenchymal Stem CellsApplication 63134535Pending
Treatment of Alzheimer's Disease With Allogeneic Mesenchymal Stem CellsApplication 63075686Pending
Potency AssayApplication 63012884Pending
Treatment Of Sexual Dysfunction And Improvement In Sexual Quality Of LifeApplication PCTUS2018037725Pending
Methods Of Using Human Mesenchymal Stem Cells To Effect Cellular And Humoral ImmunityApplication PCTUS2017061031Pending
Treatment Of Sexual Dysfunction And Improvement In Sexual Quality Of LifeApplication 62521765Pending
Mesenchymal Stem Cells As Vaccine Adjuvants And Methods For Using The SameApplication PCTUS2017016200Pending
Methods of Using Human Mesenchymal Stem Cells to Effect Cellular and Humoral ImmunityApplication 62421048Pending
Mesenchymal Stem Cells As Vaccine Adjuvants and Methods For Using the SameApplication 62291350Pending

Mozart TherapeuticsSimilar federal contract value in Biotech · null in contracts
IN CYTU, INC.Similar federal contract value in Biotech · null in contracts
VXBIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
EnKay Omics, Inc.Similar federal contract value in Biotech · null in contracts
Indapta TherapeuticSimilar federal contract value in Biotech · null in contracts
Stemsynergy TherapeuticSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.